HomeBUSINESS
BUSINESS

Nippon Shinyaku to Expand Contract Manufacturing Biz with New Facility to Start Full Operation in Feb.
(Oct.12.2018)

Nippon Shinyaku plans to begin the in-house manufacturing of its selective IP receptor agonist Uptravi (selexipag) and to expand its contract manufacturing business now that a new manufacturing plant for highly active solid formulations is expected to begin full-scale operations at the company’s Odawara Central Factory in Kanagawa Prefecture next February ...
(LOG IN FOR FULL STORY)